Bioequivalence and Bioavailability Forum 03:01 CEST

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

95% Upper bound calculation [RSABE / ABEL]

posted by Katrin_Ti - Austria, 2018-03-13 09:31  - Posting: # 18526
Views: 636

Hi,

as the guidence for acyclovir creams defines:

The replicate skin sections from donor 1 dosed with the test product may be denoted as T11,
T21, ..., Tr1, and likewise from donor 2, T12, T22, ..., Tr2, and so forth up to n donors; T1n,
T2n, ..., Trn. Similarly, the replicate skin sections dosed with the RLD product may be denoted as R1n, R2n, ..., Rrn.



That means that you need the same number of replicates from each donor (for R and T) for further calculations.

Calculate the point estimate, inter-donor variability and within reference variability using the log-transformed data (as defined in the acyclovir cream guidance).
If SWR >= 0.294 use the RSABE approach and calculate the upper bound of the CI as described in the Progesterone guidance.
I think the SAS code described in the progesterone guidance has to be modified but I can not help you with this task.

Greetings

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,698 posts in 3,983 threads, 1,234 registered users;
online 12 (0 registered, 12 guests [including 8 identified bots]).

When puzzled, it never hurts to read the primary documents –
a rather simple and self-evident principle that has, nonetheless,
completely disappeared from large sectors
of the American experience.    Stephen Jay Gould

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed